We studied the stability of 5-fluorouracii (5-FU) in plasma and whole blood kept at room temperature and on ice for 1 to 24 h. At room temperature, there was a steady loss of 94% of the parent drug over 24 h in whole blood and 52% in plasma. In the presence of an excess of uracil, 5-FU was stable for 24 h, suggesting that the loss of 5-FU is the result of enzymatic degradation. 5-FU is more stable in whole blood and plasma when samples are kept cold. For blood and plasma samples maintained on ice, the loss was only 30% and 10% of the parent drug in the respective samples over 24 h. Frozen plasma samples (-20 #{176}C) were stable for five weeks. Blood specimens collected for quantifying 5-FU should be immediately placed on ice, and the plasma should be separated and frozen as promptly as possible.
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AddItional Keyphrases: chemotherapy sample handling, stability . cancer therapy 5-Fluorouracil (5-PU) is an anticancer drug widely used for treating cancer of the gastrointestinal tract, head and neck, and breast. The unique pharmacological characteristics of this drug, such as dose-dependent clearance (1) and variable oral absorption (2), are indications for therapeutic drug monitoring. To define optimal specimen-processing methods for pharmacokinetic studies, we evaluated the stability of this drug in plasma and whole blood.
Materials and Methods
Heparinized 20-mL blood samples were obtained from six healthy volunteers, three men and three women, ages 29 to 36 years. Plasma was separated by centrifligation at 500 x g for 10 mm. Aliquots of both plasma and whole blood from each subject were supplemented with a 1 mmolJL aqueous stock solution of 5-FU (Sigma Chemical Co., St. Louis, MO) to give a final concentration of 10 pmol/L. These aliquots were kept either on ice or at room temperature. We also tested a 10 molJL solution of 5-FU in phosphate-buffered saline (PBS, NaCl 9 g/L, KH2PO4 210 mgfL, Na2HPO4 726 mg/L, pH 7.2; Biofluids, Rockville, MD) stored under the same conditions. We removed samples for assay at the following times: before the incubation and at 1, 5, and 24 h. After the incubation period, we separated plasma from the whole-blood samples by centrifugation at 500 x g for 10 mm, then stored all samples frozen (-20 #{176}C) until assay.
We also evaluated the stability of a pooled plasma sample containing 10 p.mol of 5-FU per liter that was stored at -20 #{176}C for five weeks.
5-FU in plasma was measured by reversed-phase "highpressure" liquid chromatography, with sample extraction as previously described (3).
To separate sets of blood and plasma samples from two healthy donors we added the stock 5-PU solution labeled with '4C in the 2-position on the ring (ICN Radiochemicals, Pediatric Branch, National Cancer Institute, National Institutes ofHealth, Bethesda, MD 20892.
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Irvine, CA) to give a final concentration of 10 j.mol/L and incubated these for 24 h at room temperature. Before the incubation plasma and blood were divided into three aliquota: one served as a control; we added NaF (4 g/L) to the second; and to the third we added uracil (Sigma Chemical Co.), 100 mo1/L. After the incubation, we extracted the samples and analyzed them as described above, collecting the eluted fractions each minute and counting their radioactivity with a scintillation counter.
Results and Discussion
The stability of 5-PU in plasma and whole blood, stored on ice and at room temperature for up to 24 h, is shown in Figure 1 . The most striking decrease in concentration occurred in whole blood stored at room temperature, with 94% of the drug being lost after 24 h. Under the same conditions, 52% of the drug was no longer detectable in plasma.
Blood and plasma samples kept on ice lost respectively 30% and 10% of the original drug concentration after 24 h.
A 10 anolJL solution of 5-PU in phosphate-buffered saline (pH 7.2), either stored on ice or at room temperature, showed no degradation after 24 h.
Supplemented plasma samples stored at -20 #{176}C for five weeks lost less than 10% of the original drug concentration.
The effect of competitive (uracil) and noncompetitive NaF had little effect on FU breakdown. However, an excess of uracil completely blocked degradation after 24 h at room mechanism of degradation may involve the erythrocyte. 5-PU is eliminated from the body by enzymatic degradation to inactive metabolites, via the normal catabolic pathway for uracil and thymidine. If loss of 5-PU activity from plasma and blood were a re8ult of catabolism by these enzymes, an excess of uracil would be expected to inhibit the 5-FU breakdown competitively, as we observed. Our findings suggest that 5-PU is enzymatically On the basis of these results, we recommend that blood specimens collected for 5-PU assay be placed immediately on ice, and that the plasma be separated as quickly as possible and frozen (-20 #{176}C) until analysis. 
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